Altus is Currently Recruiting Subjects for the Phase III Clinical Trial for an Investigational Enzyme Replacement Therapy in People with Pancreatic Insufficiency Resulting from Chronic Pancreatitis.

Trizytek™ (porcine-free enzymes), an investigational oral enzyme replacement product, is being evaluated as a potential therapy for malabsorption associated with pancreatic insufficiency (PI) due to chronic pancreatitis (CP), pancreatectomy, or cystic fibrosis (CF). The DIGEST Trials (Determining the efficacy and safety of an Innovative GastrointESTinal enzyme complex) will examine the safety and efficacy of Trizytek in people with PI due to CF, as well as ascertain the safety of Trizytek in people with PI due to CP. Trizytek contains three enzymes- a lipase, protease, and amylase- specifically chosen to aid in the digestion of fats, proteins, and carbohydrates. Trizytek has been studied in Phase I and Phase II clinical trials that assessed its safety, efficacy, and dosing regimen. These trials supported further testing for this producing a Phase III program.

Altus Pharmaceuticals has completed the recruitment phase of the DIGEST Trials with CF patients. We would like to thank all of the clinical sites and participants involved.

We are currently still seeking participants with chronic pancreatitis to be part of the DIGEST long-term safety study. The duration of the study is one year and participants will be asked to take the study medication with every meal or snack.

If you are interested in participating in this trial, please talk to your doctor or click on the Trial Eligibility link below to find out if you fit the basic characteristics of individuals required for this clinical trial.  You will be asked to answer a short list of questions and if you or the participant meet these qualifications, a list of participating study centers will be displayed. Select the study center nearest you and enter your contact information, which will be forwarded to the chosen center.  Additional tests of your eligibility will be conducted at the study center.

All clinical trial participants will be required to sign an informed consent with the study center prior to enrolling in the study.  Altus recommends that you consult your doctor before participating in a clinical trial.

We encourage you to learn more about clinical trials and the importance of informed consent.

Continue to the Trial Eligibility form